WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201275
CAS#: 958646-17-8
Description: Epofolate is folate receptor-targeting antimitotic agent with potential antineoplastic activity. Folate receptor-targeted epothilone BMS753493 contains an epothilone moiety linked to a single folate molecule. Mediated through the folate moiety, this agent delivers the antimitotic epothilone component into cells expressing folic acid receptors, frequently upregulated in many types of tumor cells. After ligand-receptor internalization, the epothilone moiety induces microtubule polymerization and stabilizes microtubules against depolymerization, resulting in the inhibition of mitosis and cellular proliferation. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
MedKoo Cat#: 201275
Name: Epofolate
CAS#: 958646-17-8
Chemical Formula: C67H92N16O22S3
Exact Mass: 1568.5734
Molecular Weight: 1569.743
Elemental Analysis: C, 51.27; H, 5.91; N, 14.28; O, 22.42; S, 6.13
Epofolate is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Synonym: Code name: BMS753493; BMS-753493; BMS 753493.
IUPAC/Chemical Name: (2R,5S,8S,11S,16S)-16-(4-(((2-amino-4-oxo-4,8-dihydropteridin-6-yl)methyl)amino)benzamido)-5,11-bis(carboxymethyl)-2-(((2-(((2-((1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12-tetramethyl-3-((E)-1-(2-methylthiazol-4-yl)prop-1-en-2-yl)-5,9-dioxo-4-oxa-17-azabicyclo[14.1.0]heptadecan-17-yl)ethoxy)carbonyl)oxy)ethyl)disulfanyl)methyl)-8-(3-guanidinopropyl)-4,7,10,13-tetraoxo-3,6,9,12-tetraazaheptadecanedioic acid
InChi Key: TURJYGRXEJIBGT-OCOMGVANSA-N
InChi Code: InChI=1S/C67H92N16O22S3/c1-32-9-7-11-45-46(26-47(33(2)23-38-30-106-35(4)74-38)105-52(90)27-48(84)67(5,6)55(92)34(3)54(32)91)83(45)19-20-103-66(102)104-21-22-107-108-31-44(63(100)101)80-60(96)43(25-51(88)89)79-58(94)40(10-8-18-71-64(68)69)77-59(95)42(24-50(86)87)76-49(85)17-16-41(62(98)99)78-57(93)36-12-14-37(15-13-36)72-28-39-29-73-56-53(75-39)61(97)82-65(70)81-56/h12-15,23,29-30,32,34,40-48,54,72,84,91H,7-11,16-22,24-28,31H2,1-6H3,(H,76,85)(H,77,95)(H,78,93)(H,79,94)(H,80,96)(H,86,87)(H,88,89)(H,98,99)(H,100,101)(H4,68,69,71)(H3,70,73,81,82,97)/b33-23+/t32-,34+,40-,41-,42-,43-,44-,45+,46-,47-,48-,54-,83?/m0/s1
SMILES Code: O=C(O)[C@H](CSSCCOC(OCCN([C@@]1([H])C[C@@H](/C(C)=C/C2=CSC(C)=N2)OC(C[C@H](O)C3(C)C)=O)[C@]1([H])CCC[C@H](C)[C@H](O)[C@@H](C)C3=O)=O)NC([C@H](CC(O)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(O)=O)NC(CC[C@H](NC(C4=CC=C(NCC5=CNC6=NC(N)=NC(C6=N5)=O)C=C4)=O)C(O)=O)=O)=O)=O)=O
The following data is based on the product molecular weight 1569.743 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Vlahov IR, Vite GD, Kleindl PJ, Wang Y, Santhapuram HK, You F, Howard SJ, Kim SH, Lee FF, Leamon CP. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4578-81. Epub 2010 Jun 8. PubMed PMID: 20594844.
Epofolate is a synthetic conjugate of Epothilone and folic acid. Epofolate is currently investigated by Bristol-Myers Squibb as an anticancer drug candidate. As of 2010, this agent is in Phase 1/2 clinical study. The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion). Assigned Interventions: Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses (source: http://clinicaltrials.gov/ct2/show/NCT00546247).
BMS-753493 is a molecule born from a collaboration between scientists at Endocyte Inc. and Bristol Myers Squibb (BMS). It represents a FA conjugate that was constructed with a semi-synthetic analog of Epothilone A. BMS-753493 is currently being evaluated for safety and efficacy in Phase 2 clinical trials sponsored by BMS.
BMS-753493 is a molecule born from a collaboration between scientists at Endocyte Inc. and Bristol Myers Squibb (BMS). It represents a FA conjugate that was constructed with a semi-synthetic analog of Epothilone A. BMS-753493 is currently being evaluated for safety and efficacy in Phase 2 clinical trials sponsored by BMS.
